Authors : Vibisha Victor; Ancy U.; Grace N. Raju; Vipin Venugopalan; Shaiju S. Dharan

Volume/Issue : Volume 11 - 2026, Issue 9 - September

Google Scholar : https://tinyurl.com/yc76zwxn

DOI : https://doi.org/10.38124/ijisrt/26sep398

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Multiple sclerosis is an autoimmune inflammatory demyelinating process that affects the central nervous system. It is characterized by inflammatory demyelination and neurodegeneration leading to involvement of the brain, spinal cord, and optic nerves. Relapsing-remitting multiple sclerosis (RRMS) is the most frequent type of MS and involves recurrent episodes of neurological dysfunction followed by partial or full recovery. Multifocal involvement of the central nervous system and numerous brain and spinal cord lesions constitute a difficult clinical condition necessitating early diagnosis and adequate therapy. A patient of middle age demonstrated signs and symptoms of neurological impairment related to central nervous system involvement. Brain and spinal cord magnetic resonance imaging (MRI) showed multiple demyelinating hyperintensive lesions in periventricular, juxtacortical, and infratentorial regions with concomitant spinal cord lesions. Taking into consideration the pattern and characteristics of the lesions, a diagnosis of multiple sclerosis could be established in this case. The patient was diagnosed as having relapsing multiple sclerosis. He was prescribed appropriate immunomodulatory therapy and supportive treatment. In this case, the significance of detecting multifocal demyelinating lesions in the presence of recurrent neurological manifestations is emphasized. Proper diagnosis based on MRI assessment and adequate treatment could reduce the number of relapses and the occurrence of neurological disability in the future.

Keywords : Multiple Sclerosis, Demyelination, CNS Lesions, Spinal Cord Involvement.

References :

1. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS. Mult Scler. 2020;26(14):1816-1821.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-1517.
3. Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406-419.
4. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis. Neurology. 2014;83(3):278-286.
5. Lassmann H. Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol. 2005;15(3):217-222.
6. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
7. Bot JCJ, Barkhof F, Polman CH, et al. Spinal cord abnormalities in multiple sclerosis. Radiology. 2004;233(2):531-540.
8. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on treatment of multiple sclerosis. Eur J Neurol. 2018;25(2):215-237.
9. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018; 378:169-180.
10. Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380-1390.
11. Dobson R, Giovannoni G. Multiple sclerosis: a review. Eur J Neurol. 2019;26(1):27-40.
12. Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology. 2011;259(3):659-681.
13. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31(6):752-759.
14. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545-558.
15. Tintore M, Rovira A, Río J, et al. Defining high, medium and low-risk clinically isolated syndromes. Neurology. 2015;84(7):702-709.